Business Overview: Puma Biotechnology, Inc. (NASDAQ: PBYI)

---

Executive Summary

Puma Biotechnology is a biopharmaceutical company built around a single commercial drug, NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor targeting HER1, HER2, and HER4, used to treat HER2-positive breast cancer. Puma sells NERLYNX directly in the U.S. through its own roughly 35-person specialty sales force, and relies on exclusive sub-license agreements with third parties for sales in more than 40 other countries, including the EU, China, and Canada.

To diversify beyond its single asset, Puma in-licensed alisertib, a selective Aurora Kinase A inhibitor, from Takeda in September 2022, with global development and commercialization rights. Two Phase II trials — in small cell lung cancer and in HR+/HER2-negative metastatic breast cancer — began enrolling in 2024, built on a safety database from prior trials in more than 1,300 patients. The company's strategy is explicit: grow NERLYNX within its existing label, advance alisertib, and in-license additional commercial or late-stage drugs to build a more durable, multi-product pipeline.

---

1. Core Business Model & How They Work

  NERLYNX (neratinib) — approved HER2-positive breast cancer drug
            |
   +--------+--------------------+
   |                             |
U.S. Direct Sales          Ex-U.S. Sub-License Partners
(~35 specialists)          (40+ countries: EU, China, Canada)
   |                             |
   +--------+--------------------+
            |
            v
   Revenue --> Funds alisertib clinical development (in-licensed from Takeda)
            |
            v
   Pipeline expansion via further in-licensing

---

2. Business Segments

Puma does not report distinct financial segments; its business is organized around its commercial product and pipeline:

Puma Biotechnology
├── NERLYNX (neratinib) — commercial, HER2+ breast cancer
│   ├── Extended adjuvant treatment (approved 2017)
│   └── Combination with capecitabine, advanced/metastatic (approved 2020)
└── Alisertib (in-licensed from Takeda, Sept 2022) — pipeline
    ├── ALISCA-Lung1 — Phase II, small cell lung cancer
    └── ALISCA-Breast1 — Phase II, HR+/HER2- metastatic breast cancer

---

3. Product Portfolio

Supporting studies behind NERLYNX include ExteNET (adjuvant setting), NALA (metastatic setting), and CONTROL (dose escalation to manage diarrhea, neratinib's key tolerability issue).

---

4. Competitive Landscape

Puma names Genentech, Novartis, Roche, Boehringer Ingelheim, Eli Lilly, Amgen, Daiichi Sankyo, Jazz Pharmaceuticals, and Seagen as competitors. Amgen, Daiichi Sankyo, and Jazz are developing rival small cell lung cancer drugs; others target HER2-positive breast cancer or HER2-mutant cancers, including through trials such as DESTINY-Breast05 and CompassHER2 RD.

                Large Pharma Resources
                        |
   Roche, Lilly, Amgen, Daiichi Sankyo (broad oncology portfolios)
                        |
  ----------------------+----------------------
                        |
   Puma Biotechnology    |   Smaller specialty
   (single-product,      |   oncology biotechs
   in-licensing strategy)|
                Small/Specialty Pharma Resources

---

5. Strategic Strengths & Risks

Strengths

• An established U.S. commercial infrastructure already generating revenue from NERLYNX
• A broad international sub-licensee network covering 40+ countries without Puma bearing direct commercial cost abroad
• Patent protection and regulatory exclusivity for NERLYNX in multiple jurisdictions
• A large, well-characterized alisertib safety database (1,300+ prior patients) that lowers some clinical-development risk

Risks

• Heavy dependence on a single commercial product (NERLYNX) with a relatively short commercial history
• Intense competition from much larger pharmaceutical companies with greater R&D and marketing resources
• Reliance on third-party sub-licensees, contract research organizations, and manufacturers for large parts of the business
• Ongoing European patent oppositions affecting supplementary protection certificates for NERLYNX
• Diarrhea as a notable, label-relevant side effect that affects patient tolerability and adherence
• Alisertib programs are still in Phase II, with years of development and binary trial risk ahead

---

6. Financial Overview

---

7. Summary Conclusion

Puma Biotechnology's moat is concentrated in patent-protected exclusivity and regulatory approvals for NERLYNX, extended internationally through sub-license partners rather than its own infrastructure — a capital-efficient model but one that leaves the company dependent on a single drug facing growing HER2-targeted competition. The alisertib in-licensing deal is the company's clearest attempt to build a second pillar, but with both ALISCA programs still in Phase II, Puma's near-term durability still rests almost entirely on NERLYNX holding its ground against better-resourced rivals.